Analysts expect Travere Therapeutics, Inc. to report revenue of 256.95 M for Q4 26, against a range of 235.60 M to 278.30 M. The most recent reported quarter, Q3 26, came in at 224.56 M, a 11.2% beat against the 202.02 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 73.55 M | 75.86 M | 94.84 M | 164.86 M | 129.69 M | 127.20 M | 169.58 M | 224.56 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 73.29 M | 79.77 M | 114.51 M | 113.91 M | 146.97 M | 136.72 M | 153.76 M | 219.72 M | 278.30 M | 258.91 M | 320.86 M | 319.88 M | 362.92 M | 319.65 M | 348.59 M | 414.89 M | |||||||||
| Low Estimate | 64.02 M | 68.74 M | 95.16 M | 106.74 M | 124.30 M | 120.06 M | 141.11 M | 184.32 M | 235.60 M | 240.57 M | 286.03 M | 291.77 M | 315.69 M | 297.30 M | 311.73 M | 349.51 M | |||||||||
| Consensus Estimate | 68.65 M | 74.25 M | 104.84 M | 110.33 M | 135.63 M | 128.39 M | 147.44 M | 202.02 M | 256.95 M | 249.74 M | 303.44 M | 305.82 M | 339.30 M | 308.48 M | 330.16 M | 382.20 M |
Analysts expect Travere Therapeutics, Inc. to report earnings per share of 0.45 for Q4 26, against a range of 0.43 to 0.47. The most recent reported quarter, Q3 26, came in at -0.55, a 816.7% miss against the -0.06 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.73 | -0.47 | -0.14 | 0.28 | 0.03 | -0.40 | -0.37 | -0.55 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.56 | -0.57 | -0.29 | -0.29 | 0.00 | -0.23 | -0.14 | -0.06 | 0.47 | 0.63 | 0.96 | 1.02 | 1.30 | 0.92 | 0.97 | 1.05 | |||||||||
| Low Estimate | -0.64 | -0.61 | -0.31 | -0.35 | 0.00 | -0.27 | -0.16 | -0.06 | 0.43 | 0.55 | 0.80 | 0.96 | 1.16 | 0.80 | 0.85 | 0.93 | |||||||||
| Consensus Estimate | -0.60 | -0.59 | -0.30 | -0.32 | 0.00 | -0.25 | -0.15 | -0.06 | 0.45 | 0.59 | 0.88 | 0.99 | 1.23 | 0.86 | 0.91 | 0.99 |
Pull Wall Street consensus for Travere Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TVTX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TVTX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TVTX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();